CIK 0000818686 · Large accelerated filer
TEVA PHARMACEUTICAL INDUSTRIES LTD
Sign in to watch- Ticker
- TEVA
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Israel
- Entity type
- operating
- Phone
- 972 (3) 914-8213
- Business address
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED, 124 DVORA HANEVI'A ST., TEL AVIV, Israel
- Former names
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $33,242,786
- in 10 filings, $10.6M under 10b5-1 plans
Net −$33,242,786. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-03-04 | Stark David Matthew Exec. VP Chief Legal Officer | Grant or award · Restricted Share Units | +127,345 | 127,345 | ||
| 2022-03-04 | Shani Eli EVP,Global Marketing&Portfolio | Option exercise | +3,173 | 12,264 | ||
| 2022-03-04 | Shani Eli EVP,Global Marketing&Portfolio | Option exercise · Restricted Share Units | −3,173 | 3,173 | ||
| 2022-03-04 | Shani Eli EVP,Global Marketing&Portfolio | Grant or award · Restricted Share Units | +80,428 | 80,428 | ||
| 2022-03-04 | Schultz Kare President and CEO | Option exercise | +59,701 | 1,192,197 | ||
| 2022-03-04 | Schultz Kare President and CEO | Option exercise | +162,593 | 1,354,790 | ||
| 2022-03-04 | Schultz Kare President and CEO | Option exercise · Restricted Share Units | −59,701 | 59,702 | ||
| 2022-03-04 | Schultz Kare President and CEO | Option exercise · Restricted Share Units | −162,593 | 0 | ||
| 2022-03-04 | Schultz Kare President and CEO | Grant or award · Restricted Share Units | +402,144 | 402,144 | ||
| 2022-03-04 | Sabag Mark EVP, International Markets | Option exercise | +15,920 | 110,523 | ||
| 2022-03-04 | Sabag Mark EVP, International Markets | Option exercise | +43,358 | 153,881 | ||
| 2022-03-04 | Sabag Mark EVP, International Markets | Option exercise · Restricted Share Units | −15,920 | 15,921 | ||
| 2022-03-04 | Sabag Mark EVP, International Markets | Option exercise · Restricted Share Units | −43,358 | 0 | ||
| 2022-03-04 | Sabag Mark EVP, International Markets | Grant or award · Restricted Share Units | +134,048 | 134,048 | ||
| 2022-03-04 | Kalif Eliyahu Sharon EVP, Chief Financial Officer | Grant or award · Restricted Share Units | +134,048 | 134,048 | ||
| 2022-03-04 | Inbar Galia See "Remarks" | Grant or award · Restricted Share Units | +80,428 | 80,428 | ||
| 2022-03-04 | Fridriksdottir Hafrun Executive VP, Global R&D | Option exercise | +51,488 | 116,996.51 | ||
| 2022-03-04 | Fridriksdottir Hafrun Executive VP, Global R&D | Sale | −18,020 | $7.48 | $135K | 98,976.51 |
| 2022-03-04 | Fridriksdottir Hafrun Executive VP, Global R&D | Option exercise | +18,905 | 117,881.51 | ||
| 2022-03-04 | Fridriksdottir Hafrun Executive VP, Global R&D | Sale | −6,618 | $7.48 | $50K | 111,263.51 |
Page 38 of 76 · 1,517 trades